634 related articles for article (PubMed ID: 20172849)
1. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
[TBL] [Abstract][Full Text] [Related]
2. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
[TBL] [Abstract][Full Text] [Related]
3. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.
Yamada K; Fujimoto S; Tokura T; Fukudome K; Ochiai H; Komatsu H; Sato Y; Hara S; Eto T
Ren Fail; 2005; 27(4):361-5. PubMed ID: 16060120
[TBL] [Abstract][Full Text] [Related]
4. RenaGel efficacy in severe secondary hyperparathyroidism.
Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
Wilkes BM; Reiner D; Kern M; Burke S
Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
[TBL] [Abstract][Full Text] [Related]
7. IL-18 is involved in vascular injury in end-stage renal disease patients.
Porazko T; Kúzniar J; Kusztal M; Kúzniar TJ; Weyde W; Kuriata-Kordek M; Klinger M
Nephrol Dial Transplant; 2009 Feb; 24(2):589-96. PubMed ID: 18775894
[TBL] [Abstract][Full Text] [Related]
8. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.
Kakuta T; Tanaka R; Hyodo T; Suzuki H; Kanai G; Nagaoka M; Takahashi H; Hirawa N; Oogushi Y; Miyata T; Kobayashi H; Fukagawa M; Saito A
Am J Kidney Dis; 2011 Mar; 57(3):422-31. PubMed ID: 21239096
[TBL] [Abstract][Full Text] [Related]
9. Ten-year experience with sevelamer and calcium salts as phosphate binders.
Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
[TBL] [Abstract][Full Text] [Related]
10. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients.
Wang AY; Woo J; Lam CW; Wang M; Chan IH; Gao P; Lui SF; Li PK; Sanderson JE
Nephrol Dial Transplant; 2005 Aug; 20(8):1676-85. PubMed ID: 15899935
[TBL] [Abstract][Full Text] [Related]
11. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H;
Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients.
Lin HH; Liou HH; Wu MS; Huang CC
BMC Nephrol; 2016 Mar; 17():33. PubMed ID: 27007989
[TBL] [Abstract][Full Text] [Related]
13. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.
Garg JP; Chasan-Taber S; Blair A; Plone M; Bommer J; Raggi P; Chertow GM
Arthritis Rheum; 2005 Jan; 52(1):290-5. PubMed ID: 15641045
[TBL] [Abstract][Full Text] [Related]
14. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
15. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
Negri AL
J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
[TBL] [Abstract][Full Text] [Related]
16. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
[TBL] [Abstract][Full Text] [Related]
18. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.
Honda H; Qureshi AR; Heimbürger O; Barany P; Wang K; Pecoits-Filho R; Stenvinkel P; Lindholm B
Am J Kidney Dis; 2006 Jan; 47(1):139-48. PubMed ID: 16377395
[TBL] [Abstract][Full Text] [Related]
19. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
Sun PP; Perianayagam MC; Jaber BL
J Ren Nutr; 2009 Sep; 19(5):432-8. PubMed ID: 19464926
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]